AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Neurodiagnostics Market Expected to Grow with a CAGR of 7.3% During the Forecast Period, 2019-2024 - ResearchAndMarkets.com

January 6, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 6, 2020--

The  “Neurodiagnostics Market by Product (Diagnostic & Imaging Systems (MRI, Ultrasound), Clinical Testing (PCR, NGS), Reagents & Consumables), Disease Pathology (Epilepsy, Stroke), End User, and Region - Global Forecast to 2024”  report has been added to  ResearchAndMarkets.com’s  offering.

The global neurodiagnostics market is projected to grow at a CAGR of 7.3% during the forecast period.

The global neurodiagnostics market is expected to reach USD 8.4 billion by 2024 from USD 5.9 billion in 2019, at a CAGR of 7.3%. The demand for neurodiagnostic products is expected to grow due to the increasing prevalence of neurological disorders & diseases. The neurodiagnostics market is segmented on product, condition, end-user, and region.

The hospitals & surgical centers segment accounted for the largest share of the neurodiagnostics market by end-user in 2018.

Based on end-user, the neurodiagnostics market is segmented into hospitals & surgical centers, diagnostic laboratories & imaging centers, neurology centers, ambulatory care centers (ACCs), and research laboratories & academic institutes. In 2018, hospitals & surgical centers accounted for the largest share of the neurodiagnostics market due to the financial capabilities of hospitals to purchase expensive equipment, such as neurodiagnostic devices.

The neurodegenerative diseases segment accounted for the largest share of the neurodiagnostics market by condition in 2018.

The neurodiagnostics market, by condition, is segmented into neurodegenerative diseases, epilepsy, stroke, headache disorders, sleep disorders, and other conditions. In 2019, the neurodegenerative diseases segment is expected to account for the largest share of the neurodiagnostics market due to the increasing incidence of traumatic brain injuries, dementia, Parkinson’s disease, and Huntington’s disease, and the growing number of neurological examinations for the diagnosis of these conditions.

North America accounted for the largest share of the neurodiagnostics market in 2018.

North America accounted for the largest share of the neurodiagnostics market in 2018, followed by Europe. This can primarily be attributed to the presence of a highly developed healthcare system, high adoption of innovative neurodiagnostic devices among medical professionals, full availability of advanced neurodiagnostic tools, and the large number of neurodiagnostic devices manufacturing companies that have an established base or are headquartered in the US.

Research Coverage

This report studies the neurodiagnostics market based on product, condition, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. It analyzes micromarkets with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.

Key Benefits of Buying the Report

This report focuses on various levels of analysis - industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscape; emerging segments of the neurodiagnostics market; and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

Key Topics Covered:

1 Introduction

1.1 Objectives of the Study

1.2 Market Definition

1.3 Market Scope

1.4 Currency Used for the Study

1.5 Major Market Stakeholders

2 Research Methodology

2.1 Research Data

2.2 Market Estimation Methodology

2.3 Data Triangulation

2.4 Research Assumptions

2.5 Research Limitations

3 Executive Summary

4 Premium Insights

4.1 Market Overview

4.2 Neurodiagnostics Market, By Product, 2019 Vs. 2024

4.3 Market Share, By End User and Region (2019)

4.4 Market, By Condition, 2019 Vs. 2024 (USD Million)

4.5 Market, By Country

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.2 Restraints

5.2.3 Opportunities

5.2.4 Challenges

6 Neurodiagnostics Market, By Product

6.1 Introduction

6.2 Diagnostic Imaging Systems

6.3 Clinical Diagnostic Instruments

6.4 Reagents & Consumables

7 Neurodiagnostics Market, By Condition

7.1 Introduction

7.2 Neurodegenerative Diseases

7.3 Stroke

7.4 Epilepsy

7.5 Headache Disorders

7.6 Sleep Disorders

8 Neurodiagnostics Market, By End User

8.1 Introduction

8.2 Hospitals & Surgical Centers

8.3 Diagnostic Laboratories & Imaging Centers

8.4 Neurology Centers

8.5 Ambulatory Care Centers

8.6 Research Laboratories & Academic Institutes

9 Neurodiagnostics Market, By Region

9.1 Introduction

9.2 North America

9.3 Europe

9.4 Asia Pacific

9.5 Latin America

9.6 Middle East & Africa

10 Competitive Landscape

10.1 Overview

10.2 Market Share Analysis

10.3 Competitive Scenario

10.4 Competitive Leadership Mapping

11 Company Profiles

11.1 GE Healthcare

11.2 Philips Healthcare

11.3 Siemens Healthineers

11.4 Hitachi, Ltd.

11.5 Canon, Inc.

11.6 Lifelines Neuro Company, LLC

11.7 Natus Medical Incorporated

11.8 F. Hoffmann-La Roche AG

11.9 FUJIFILM Holdings Corporation

11.10 Mitsar Co., Ltd.

11.11 Advanced Brain Monitoring, Inc.

11.12 Thermo Fisher Scientific, Inc.

11.13 Bio-Rad Laboratories

11.14 QIAGEN N.V.

11.15 Nihon Kohden Corporation

11.16 Other Companies

11.16.1 ANT Neuro

11.16.2 Fonar Corporation

11.16.3 Fujirebio (A Part of Miraca Group)

11.16.4 DRG Instruments GmbH

11.16.5 Tecan Trading AG

For more information about this report visit  https://www.researchandmarkets.com/r/hvqhqe

View source version on businesswire.com:https://www.businesswire.com/news/home/20200106005633/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES OTHER HEALTH GENERAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/06/2020 09:41 AM/DISC: 01/06/2020 09:41 AM

http://www.businesswire.com/news/home/20200106005633/en